How to Choose a Toll Manufacturer for Pharma: What Actually Predicts a Good Partnership

TL;DR: Most pharma companies vet toll processing partners on capacity and price. The evaluations that actually predict a good partnership look at how a processor handles ambiguity, communicates problems, and flexes when a project doesn’t go according to spec. Here’s what to check instead, from a toll processor who’s sat on both sides of the table.

Most guides on how to choose a toll manufacturer start with capacity, equipment, and certifications. A pharma manufacturer puts together an RFP listing exactly those things, and every qualified toll processor checks the boxes. They’re the easy questions with easy answers. Then, four months into the partnership, something the RFP never asked about goes wrong: a batch runs into an issue the spec sheet didn’t anticipate, and the company finds out how its processor actually behaves under pressure.

That gap between what pharma teams evaluate and what actually predicts a good toll processing partnership is where a lot of vendor selections go sideways.

Why Pharma Companies Outsource Toll Processing in the First Place

The decision to outsource rarely comes down to one factor. Capital cost is usually part of it: building in-house milling, grinding, or blending capacity for pharma-grade material means cleanrooms, specialized equipment, and a cGMP quality system, all before a single batch ships. Speed to market is another. A company that needs to scale from lab quantities to commercial volume doesn’t always have a year to spare building that capacity itself.

What changes once a pharma company brings in a toll partner is real, and companies don’t always plan for it. They gain equipment and expertise they’d otherwise have to build from scratch. They also give up a degree of direct control over a process step that used to happen inside their own walls. Timing can push a company to outsource, but the more common trigger is narrower: a product that needs a specific piece of equipment, such as a particular mill, at a volume too small to justify buying it. The company may not have the expertise to develop a process on equipment it doesn’t own. Or it may not want to commit a cleanroom to a small unit operation when that room is more productive running other processing steps.

The Vetting Mistake That Predicts a Bad Partnership

Most RFPs and audit checklists are built around capacity claims and compliance documentation. Those matter. But they miss the question that actually predicts whether a partnership holds up: how does this processor behave when a project doesn’t go exactly according to the spec sheet?

A toll processor that simply checks the boxes on a spec sheet looks identical to one that can flex with a project as it evolves — right up until something unplanned happens. The difference shows up in a handful of concrete signals:

● Capacity that exists on paper but not in your time frame: a processor can have the right equipment and still lack an open slot because of other committed projects, so ask for an actual production window and verify it

● Inspection history beyond the cGMP approval itself, including when the regulatory authority last inspected the site and what that inspection covered

● How the processor decides what counts as a deviation, and how and when it communicates one to you

● Process knowledge, meaning enough experience to deliver an economical process that keeps development and start-up material, which typically becomes unsaleable waste, to a minimum

A cGMP approval tells you the regulatory authority has scrutinized the quality system. The inspection record tells you how recently and how deeply. That history is harder to fake than a capacity number, and most RFPs give it less weight than it deserves.

What a Healthy Partnership Looks Like Once Work Begins

Some pharma toll processing work, tech transfer projects in particular, comes with extensive customer specifications. Even then, the processor has real influence on how the process is executed against the target specifications, in areas like cycle time and yield. Other projects give the processor more latitude to bring its process knowledge to the table. Reading which kind of project you’re in, and adjusting accordingly, is part of what separates a processor that partners well from one that just executes instructions.

Once a partnership is underway, keeping communication and documentation on track matters more than any single technical capability. Issues that surface early get resolved before they turn into a batch failure or a missed delivery. Issues that get discovered late get expensive. That’s an operational reality more than a partner-specific one, but it’s the piece pharma companies most often underweight when they’re choosing a partner off a proposal instead of a track record.

Where CPS Fits for Pharma Customers

CPS operates a cGMP facility in Reading, Pennsylvania, built for the particle size engineering pharma and specialty ingredient manufacturers rely on: jet milling, micronization, and precision blending, among other processes. Where CPS differs from a generalist contract manufacturer is its track record of pushing existing milling and grinding technology past the limits the equipment manufacturers themselves treat as fixed, on behalf of customers who need tighter specs or better throughput than the standard setup delivers.

CPS is best suited to large-volume processing and to projects that combine several physical operations, such as milling, blending, and screening. Because the team works with a range of milling equipment, it can select the mill that fits the process and hits a well-defined particle size distribution.

For a company weighing whether to build in-house toll capability versus partnering with a processor like CPS, the honest trade-off conversation is about ongoing reliability, not just upfront cost. A pharma customer with continuous supply obligations needs a partner who’s consistent across dozens of runs, not just capable on the first one.

What to Prioritize When You're Just Starting to Evaluate Partners

If your team is early in the process of vetting toll processing partners, four things are worth prioritizing over everything else on a standard RFP checklist:

1. Ask how the processor handles a project that changes mid-stream, not just how they handle one that goes according to plan.
   

2. Weight the quality and regulatory track record as heavily as technical capability. Ask when the last regulatory inspection took place and what it covered, and agree up front on how and when quality issues will be communicated to you.
   

3. Talk to the processor’s existing customers about communication, not just output quality.
   

4. Spell out your expectations beyond the specifications, such as yield, cycle time, and scheduling windows, before the first batch runs.

The signal that it’s time to stop managing a process in-house and start looking seriously at a toll partner usually isn’t a single dramatic failure. It’s the slow accumulation of capacity you can’t flex, quality documentation you’re building from scratch, and engineering hours going toward a process that isn’t your core product.

If your team is evaluating toll processing partners for pharma-grade material and wants a partner with the pharma quality experience and technical flexibility to get it right, the team at CPS can walk through what a good fit looks like for your specific project.